sb 203580 has been researched along with ditiocarb in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ditiocarb) | Trials (ditiocarb) | Recent Studies (post-2010) (ditiocarb) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,897 | 22 | 224 |
| Protein | Taxonomy | sb 203580 (IC50) | ditiocarb (IC50) |
|---|---|---|---|
| Gasdermin-D | Homo sapiens (human) | 0.4 | |
| Gasdermin-D | Mus musculus (house mouse) | 0.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chilian, WM; Kolz, C; Potter, B; Reed, R; Rocic, P | 1 |
1 other study(ies) available for sb 203580 and ditiocarb
| Article | Year |
|---|---|
Optimal reactive oxygen species concentration and p38 MAP kinase are required for coronary collateral growth.
Topics: Acetophenones; Animals; Blood Flow Velocity; Cells, Cultured; Collateral Circulation; Coronary Circulation; Coronary Vessels; Disease Models, Animal; Ditiocarb; Endothelial Cells; Enzyme Inhibitors; Humans; Imidazoles; Ligation; Male; MAP Kinase Signaling System; Myocardial Reperfusion Injury; NADPH Oxidases; Neovascularization, Physiologic; Onium Compounds; Oxygenases; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; Rats, Inbred WKY; Reactive Oxygen Species; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2007 |